Association of Biomarkers With Intracerebral Hematoma Expansion and Arterial Thromboembolic Events in Patients With Acute Intracranial Hemorrhage: The ANNEXA-I Biomarker Substudy
Stroke · 2025
DOI: 10.1161/strokeaha.124.049966 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2025. Verfasst von John W Eikelboom und 10 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Research Institute, Hamilton Health Sciences and McMaster University (J.W.E., M.S., L.X., A.S.). Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Thromboembolism, Hematoma, Intracranial Hemorrhages. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors) was a randomized trial that demonstrated that andexanet compared with usual care in patients with intracranial hemorrhage associated with FXa (factor Xa) inhibitor treatment reduces the risk of hematoma expansion and increases the risk of arterial thromboembolic events. METHODS: In a secondary analysis of the ANNEXA-I trial, we compared the effects of andexanet with usual care on change in anti-FXa activity and endogenous thrombin potential (ETP) using Wilcoxon rank-sum test. We examined the associations between 1-hour reduction in anti-FXa and 1-hour increase in ETP and hematoma expansion at 12 hours (≥12.5 mL or percentage volume change ≥35%) using logistic regression, both unadjusted and adjusted for time from symptom onset to baseline scan, baseline diastolic blood pressure, hematoma volume, baseline biomarker level and time from baseline scan to treatment, and association with arterial thromboembolic events (ischemic stroke, myocardial infarction, and systemic embolism) during 30 days of follow-up using Cox regression, both unadjusted and adjusted for age, baseline biomarker level, prior myocardial infarction, and eligibility for treatment with high-dose andexanet. RESULTS: ANNEXA-I enrolled 530 patients. Among 438 patients with baseline anti-FXa results, andexanet compared with usual care reduced anti-FXa activity at 1 hour (median, 8.6 versus 97.5 ng/mL; median reduction from baseline, 98.3 versus 10.9 ng/mL; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Population Health Research Institute, Hamilton Health Sciences and McMaster University (J.W.E., M.S., L.X., A.S.).
- AstraZeneca BioPharmaceuticals R&D (K.B., C.F., P.L., R.N., R.C.P.).
- Division Thrombosis and Hemostasis, Department of Medicine I, Dresden University Hospital "Carl Gustav Carus," Technical University Dresden, Germany (J.B.-W.).
- KU Leuven Department of Cardiovascular Sciences, Belgium (P.V.).
ORCID-Profile: John W Eikelboom, Mukul Sharma, Krister Bamberg, Jan Beyer-Westendorf, Per Ladenvall, Robert C Penland, Peter Verhamme, Ashkan Shoamanesh
Zitieren
APA
Eikelboom, J. W., Sharma, M., Xu, L., Bamberg, K., Beyer-Westendorf, J., Falkenberg, C., Ladenvall, P., Narayan, R., Penland, R. C., Verhamme, P., & Shoamanesh, A. (2025). Association of Biomarkers With Intracerebral Hematoma Expansion and Arterial Thromboembolic Events in Patients With Acute Intracranial Hemorrhage: The ANNEXA-I Biomarker Substudy. Stroke. https://doi.org/10.1161/strokeaha.124.049966
Vancouver
Eikelboom JW, Sharma M, Xu L, Bamberg K, Beyer-Westendorf J, Falkenberg C, et al. Association of Biomarkers With Intracerebral Hematoma Expansion and Arterial Thromboembolic Events in Patients With Acute Intracranial Hemorrhage: The ANNEXA-I Biomarker Substudy. Stroke. 2025. doi:10.1161/strokeaha.124.049966
BibTeX
@article{Eikelboom2025,
author = {Eikelboom, John W and Sharma, Mukul and Xu, Lizhen and Bamberg, Krister and Beyer-Westendorf, Jan and Falkenberg, Cecilia and Ladenvall, Per and Narayan, Rohit and Penland, Robert C and Verhamme, Peter and Shoamanesh, Ashkan},
title = {Association of Biomarkers With Intracerebral Hematoma Expansion and Arterial Thromboembolic Events in Patients With Acute Intracranial Hemorrhage: The ANNEXA-I Biomarker Substudy},
journal = {Stroke},
year = {2025},
doi = {10.1161/strokeaha.124.049966}
}
EUVIMED